Johnson & Johnson Q3 sales rise on MedTech growth, lifts 2026 outlook
JNJ•Johnson & Johnson reported third-quarter sales of $25.40 billion, up 5.9%, and adjusted earnings of $2.59 per share, both above analyst expectations. It raised 2026 guidance to $101.2 billion in reported sales and adjusted earnings of $11.10 per share at the midpoint.
1. Quarterly results
Third-quarter sales rose 5.9% to $25.40 billion, slightly above the $25.28 billion analyst consensus. Adjusted earnings were $2.59 per share, compared with expectations of $2.54; net income was $210 million and earnings per share were $0.09. The company said growth was driven by new Immunology products and strong performance in Oncology and Neuroscience.
2. Raised 2026 outlook
Johnson & Johnson raised its 2026 reported sales guidance to $101.2 billion at the midpoint, implying growth of 7.4%, and increased its adjusted earnings guidance to $11.10 per share at the midpoint. MedTech growth was led by cardiovascular electrophysiology products, contact lenses and orthopaedics trauma. Third-quarter earnings per share were reduced by one-time charges related to talc litigation, the Firefly Bio acquisition and the Sail Biomedicines collaboration.
